144
Views
11
CrossRef citations to date
0
Altmetric
Research Article

CXCR2 Expression on Neutrophils is Upregulated During the Relapsing Phase of Ocular Behçet Disease

, , , , &
Pages 195-203 | Received 19 Feb 2004, Accepted 19 Jul 2004, Published online: 02 Jul 2009
 

Abstract

Purpose: To search for markers of Behçet disease (BD) activity, we measured CXCR1 and CXCR2 levels on the circulating leukocytes of patients suffering from ocular BD. Methods: Peripheral blood leukocytes were harvested from healthy volunteers (n = 16) and ocular BD patients (n = 35). The patients consisted of 15 individuals in relapsing phase (6 with prednisolone treatment) and 20 individuals in remission phase (9 with prednisolone treatment). Expression of CXC chemokine receptors (CXCRs) on leukocytes (including lymphocytes, monocytes, neutrophils) was measured using flow cytometry. Results: Without prednisolone treatment, CXCR2 expression (on both total leukocytes and neutrophils) in relapsing phase was significantly higher than in remission-phase patients or normal individuals. By contrast, no significant difference was detected in the expression of CXCR1 between any of the groups. Importantly, low-dose prednisolone therapy reduced CXCR2 expression on neutrophils. Conclusions: CXCR2 has a potential role in promoting uveitis during ocular attack and might also be a useful marker for disease activity.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.